Schroder Ventures
37
28M
31
0.17
7
0.16
19
- Stages of investment
- Areas of investment
Summary
Schroder Ventures is the famous VC, which was founded in 1804. The main office of represented VC is situated in the London. The fund was located in Europe if to be more exact in United Kingdom.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Schroder Ventures, startups are often financed by A.G. Edwards Capital Partners, InterWest Partners, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Abingworth, Atlas Venture, A.G. Edwards Capital Partners. In the next rounds fund is usually obtained by SV Health Investors, Oakwood Medical Investors, Fletcher Spaght, Inc..
This organization was formed by Nicholas Ferguson.
Among the most popular portfolio startups of the fund, we may highlight Auxilium Pharmaceuticals, Dynogen Pharmaceuticals, Avera Pharmaceutical. Among the most popular fund investment industries, there are Therapeutics, Medical. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. When the investment is from Schroder Ventures the average startup value is 10-50 millions dollars. The important activity for fund was in 2004. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Schroder Ventures performs on 24 percentage points more the average number of lead investments. The increased amount of exits for fund were in 2017.
Investments analytics
Analytics
- Total investments
- 37
- Lead investments
- 7
- Exits
- 19
- Rounds per year
- 0.17
- Follow on index
- 0.16
- Investments by industry
- Biotechnology (18)
- Health Care (13)
- Medical (9)
- Pharmaceutical (8)
- Medical Device (8) Show 34 more
- Investments by region
-
- United States (29)
- United Kingdom (4)
- Germany (2)
- Singapore (1)
- Peak activity year
- 2004
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 24
- Avg. valuation at time of investment
- 117M
- Group Appearance index
- 0.95
- Avg. company exit year
- 15
- Avg. multiplicator
- 2.06
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Avera Pharmaceutical | 05 Aug 2004 | Biotechnology, Health Care, Pharmaceutical | Late Stage Venture | 48M | United States, California, Carlsbad |
| Rinat Neuroscience | 20 Aug 2003 | Biotechnology, Neuroscience, Therapeutics | Early Stage Venture | 40M | United States, California, Palo Alto |
| Smartface Inc. | 01 Dec 2015 | Information Technology, Mobile, SaaS, Enterprise Software, Cloud Computing, iOS, Android | Seed | United States, California, Palo Alto |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.